Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 13/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 2/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 7/20 | 0.79 |
| ▸ | DNMT1 | P26358 | 6/20 | 0.77 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.77 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.77 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.77 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.77 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.77 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.77 |
| ▸ | INMT | O95050 | 1/20 | 0.77 |
| ▸ | NSD2 | O96028 | 1/20 | 0.77 |
| ▸ | PNMT | P11086 | 1/20 | 0.77 |
| ▸ | NNMT | P40261 | 1/20 | 0.77 |
| ▸ | HNMT | P50135 | 1/20 | 0.77 |
| ▸ | WDR5 | P61964 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.77 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.77 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191440 | 1.00 | DOT1L (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL14174642 | 1.00 | DOT1L (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL14191355 | 0.91 | DOT1L (0.85) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL14174645 | 0.91 | DOT1L (0.85) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL14174641 | 0.88 | DOT1L (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL18272513 | 0.88 | DOT1L (0.81) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL30979354 | 0.88 | DOT1L (0.84) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL30225596 | 0.88 | DNMT3B (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL17309752 | 0.88 | DNMT3B (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 | |
| SCHEMBL14174638 | 0.88 | DNMT3B (1.00) | DOT1LPRMT1DNMT3BDNMT1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
| EP-4746922-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025019776-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-118853707-A | Sichuan orange methyl esterase CmMES1.1 and CmMES1.5 genes and application thereof | 湖北省农业科学院果树茶叶研究所 | 2024-10-29 | — | — | CN | disclosed |
| EP-4146809-A1 | LARGE SCALE PRODUCTION OF OLIVETOL, OLIVETOLIC ACID AND OTHER ALKYL RESORCINOLS BY FERMENTATION | Lygos, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4021431-A1 | TREATMENT OR PREVENTION OF LEUKAEMIA | Vestlandets Innovasjonsselskap AS (NO) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022094148-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | Encodia, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200239921-A1 | CHEMOENZYMATIC SYNTHESIS OF S-NUCLEOSYL AMINO ACIDS (SNA), ANALOGS OF S-ADENOSYL-L-METHIONINE AND S-ADENOSYL-L- HOMOCYSTEINE AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2020-07-30 | — | — | US | disclosed |
| US-20140100184-A1 | SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L | BAYLOR COLLEGE OF MEDICINE (US) | 2014-04-10 | — | — | US | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239921-A1 | CHEMOENZYMATIC SYNTHESIS OF S-NUCLEOSYL AMINO ACIDS (SNA), ANALOGS OF S-ADENOSYL-L-METHIONINE AND S-ADENOSYL-L- HOMOCYSTEINE AND USES THEREOF | SHMT1, BHMT2, AHCY | DOT1L 1010/4885PRMT1 617/4885DNMT3B 402/4885 |
| US-20140100184-A1 | SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L | CARM1, DOT1L, PRMT1 | DOT1L 2/4885PRMT1 3/4885DNMT3B 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.